Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance—a study of the OVCAD consortium

E Obermayr, DC Castillo-Tong, D Pils, P Speiser… - Gynecologic …, 2013 - Elsevier
OBJECTIVE: The study aims at identifying novel markers for circulating tumor cells (CTCs) in
patients with epithelial ovarian cancer (EOC), and at evaluating their impact on outcome …

Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD data

S Polterauer, I Vergote, N Concin, I Braicu… - International Journal of …, 2012 - ijgc.bmj.com
Objective The objective of the study was to evaluate the prognostic impact of residual tumor
size after cytoreductive surgery in patients with epithelial ovarian cancer. Methods In this …

USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability

M Sonego, I Pellarin, A Costa, GLR Vinciguerra… - Science …, 2019 - science.org
Resistance to platinum-based chemotherapy is a common event in patients with cancer,
generally associated with tumor dissemination and metastasis. Whether platinum treatment …

Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer

JM Flanagan, A Wilson, C Koo, N Masrour… - Clinical Cancer …, 2017 - AACR
Purpose: DNA damage repair can lead to epigenetic changes. DNA mismatch repair
proteins bind to platinum DNA adducts and at sites of DNA damage can recruit the DNA …

[HTML][HTML] Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients-a study of the OVCAD consortium

A Bachmayr-Heyda, S Aust, G Heinze, S Polterauer… - BMC cancer, 2013 - Springer
Background Epithelial ovarian cancer is one of the most lethal gynecologic malignancies.
Clinicopathological factors do not permit precise prognosis and cannot provide guidance to …

[HTML][HTML] Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients–a study of the OVCAD consortium

D Pils, A Bachmayr-Heyda, K Auer, M Svoboda… - European journal of …, 2014 - Elsevier
Cyclin E, coded by the genes CCNE1 and CCNE2, is the main regulator for transition from G
1 to S phase determining cell division. CCNE1 and CCNE2 are known oncogenes in many …

[HTML][HTML] Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer

S Lambrechts, D Smeets, M Moisse, EI Braicu… - European Journal of …, 2016 - Elsevier
Background Most high-grade serous ovarian carcinoma (HGSOC) patients benefit from first-
line platinum-based chemotherapy, but progressively develop resistance during subsequent …

[HTML][HTML] Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium

F Trillsch, L Woelber, C Eulenburg, I Braicu… - Journal of ovarian …, 2013 - Springer
Background Approximately one third of women diagnosed with ovarian cancer is 70 years or
older. Information on the treatment reality of these elderly patients is limited. Methods 275 …

[HTML][HTML] Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium

E Obermayr, N Bednarz-Knoll, B Orsetti, HU Weier… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Purpose In 75% of ovarian cancer patients the tumor mass is completely eradicated by
established surgical and cytotoxic treatment; however, the majority of the tumors recur within …

A complex network of tumor microenvironment in human high-grade serous ovarian cancer

C Kreuzinger, A Geroldinger, D Smeets, EI Braicu… - Clinical Cancer …, 2017 - AACR
Purpose: Most high-grade serous ovarian cancer (HGSOC) patients develop recurrent
disease after first-line treatment, frequently with fatal outcome. This work aims at studying the …